Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Niels S. Vermeer
Observed names:
N S Vermeer,
N. Vermeer,
N.S. Vermeer,
NS Vermeer,
Niels S Vermeer,
Niels Vermeer,
Vermeer, Niels
show all 7
Institutions:
Amsterdam UMC Location University of Amsterdam,
Amsterdam University Medical Centers
Observed institutions:
Utrecht University,
Erasmus MC,
Amsterdam UMC Location University of Amsterdam,
Medicines Evaluation Board,
Amsterdam University Medical Centers,
Amsterdam UMC Location Vrije Universiteit Amsterdam
show all 6
ORCID:
0009-0006-5723-5371
Observed ORCID:
0009-0006-5723-5371
OpenAlex ID:
A5109259532
Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases
2013
·
Niels S. Vermeer
, Sabine M. J. M. Straus
, et al.
·
Drug Safety
·
78
Traceability of biologicals: present challenges in pharmacovigilance
2014
·
Niels S Vermeer
, Irina Spierings
, et al.
·
Expert Opinion on Drug Safety
·
50
Risk Management Plans as a Tool for Proactive Pharmacovigilance: A Cohort Study of Newly Approved Drugs in Europe
2014
·
N S Vermeer
, R G Duijnhoven
, et al.
·
Clinical Pharmacology & Therapeutics
·
44
Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice
2018
·
Niels S. Vermeer
, Thijs J. Giezen
, et al.
·
Clinical Pharmacology & Therapeutics
·
40
PDF
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports
2015
·
Kevin Klein
, Joep H. G. Scholl
, et al.
·
Drug Safety
·
38
PDF
Association of isolated short fetal femur with intrauterine growth restriction
2013
·
N. Vermeer
, M. N. Bekker
·
Prenatal Diagnosis
·
29
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
2022
·
Edwin A. Basak
, Niels S. Vermeer
, et al.
·
European Journal of Cancer
·
27
Drug‐induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab
2015
·
NS Vermeer
, SMJM Straus
, et al.
·
Clinical Pharmacology & Therapeutics
·
23
The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product‐specific risks for biologicals: a simulation study
2015
·
Niels S. Vermeer
, Hans C. Ebbers
, et al.
·
Pharmacoepidemiology and Drug Safety
·
10
PDF
Hepatic Safety Considerations in the Use of Ulipristal Acetate for Symptomatic Uterine Fibroids
2025
·
Annika Semmler
, Maria de Lange
, et al.
·
Therapeutics and Clinical Risk Management
·
8
PDF
Strategy in Regulatory Decision‐Making for Management of Progressive Multifocal Leukoencephalopathy
2015
·
A Segec
, B Keller‐Stanislawski
, et al.
·
Clinical Pharmacology & Therapeutics
·
4
Harmful Effects of Proton Pump Inhibitors: Discrepancies Between Observational Studies and Randomized Clinical Trials
2013
·
Arief Lalmohamed
, Niels Vermeer
, et al.
·
JAMA Internal Medicine
·
3
Pharmacovigilance of biologicals : dynamics in post-approval safety learning
2015
·
Vermeer, Niels
·
Utrecht University Repository (Utrecht University)
·
2
Roles and perceived responsibilities of investigators and pharmacists in the monitoring of drug-drug interactions in clinical trials - a mixed methods study
2026
·
Anne-Jaël Elskamp
, Shirley Cao
, et al.
·
Exploratory Research in Clinical and Social Pharmacy
PDF
1863P Incidence and predictors of severe adverse events during anti-PD-1 treatment
2021
·
E.A. Basak
, N.S. Vermeer
, et al.
·
Annals of Oncology
Development of safety concerns within RMPs after approval: A cohort study of biologicals
2013
·
Niels S. Vermeer
, Ruben G. Duijnhoven
, et al.
·
Drug Safety
[Research into the risk of malignancy from biologicals: utility of meta-analysis hampered].
2013
·
Niels S Vermeer
, Marie L De Bruin
·
PubMed
Show more works
View as search
Works count:
17
Citation count:
356
H-index:
9
I10-index:
9
Year
Topic
Type